NCT05316480View on ClinicalTrials.gov

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

December 30, 2026

Conditions
Pancreatic Neuroendocrine Neoplasm
Interventions
DRUG

Nimotuzumab

nimotuzumab 200mg/week

Trial Locations (1)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER